Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 4/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.34 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13046561 | 0.90 | NAMPT (0.44) | POLBNAMPTLMNAHTTALDH1A1 | |
| SCHEMBL13045644 | 0.90 | POLB (0.41) | POLBNAMPTSIRT2SIRT1SIRT3 | |
| SCHEMBL13047095 | 0.90 | POLB (0.41) | POLBNAMPTSIRT2SIRT1SIRT3 | |
| SCHEMBL13045696 | 0.90 | POLB (0.41) | POLBNAMPTSIRT2SIRT1SIRT3 | |
| SCHEMBL13046338 | 0.89 | QPCT (0.42) | POLBSIRT2SIRT1SIRT3LMNA | |
| SCHEMBL13449943 | 0.84 | IKBKB (0.38) | POLBNAMPT | |
| SCHEMBL13046673 | 0.82 | NAMPT (0.45) | NAMPTNPY5RALDH1A1CYP3A4 | |
| SCHEMBL13045695 | 0.82 | NAMPT (0.45) | NAMPTNPY5RALDH1A1CYP3A4 | |
| SCHEMBL13045387 | 0.81 | MAPKAPK2 (0.47) | CYP3A4 | |
| SCHEMBL13045700 | 0.80 | NAMPT (0.35) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TopoTarget (DE) | 2012-10-18 | — | — | US | disclosed |
| WO-2010142735-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TOPOTARGET A/S (DK) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | NAMPT, NAPRT, NNT | POLB 1516/4885NAMPT 1/4885NPY5R 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.